SynthesisNeurosurgical review2025
Intrathecal nicardipine for cerebral vasospasm after non-traumatic subarachnoid hemorrhage: a meta-analysis.
Synthesis in Neurosurgical review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cerebral vasospasm is a common and serious complication following non-traumatic subarachnoid hemorrhage (SAH), often leading to worsened outcomes, especially when associated with delayed cerebral ischemia (DCI). Intrathecal nicardipine has shown potential as a treatment for vasospasm, although further research is needed to establish its effectiveness and determine its role in managing this complication. A systematic search was conducted through MEDLINE, Embase, Cochrane Library, and Web of Science databases to identify studies comparing outcome measures for intrathecal nicardipine after SAH with a control group. The primary endpoints were vasospasm severity, DCI rate, and favorable outcome at 1-6 months, assessed by functional outcome scales. Secondary outcomes included mortality, infection rates, and the need for shunt placement. A total of six studies met the eligibility criteria, and a meta-analysis using a random-effects model was conducted to pool the data. In the data analyses of 2,569 patients, in comparison with standard therapy, nicardipine use has shown statistical significance in reducing the incidence of mild vasospasm (odds ratio [OR] = 0.40; 95% confidence interval [CI] [0.20, 0.80]; p = 0.010; 𝐼² = 0%), reducing mortality rate (OR = 0.58; 95% CI [0.42, 0.81]; p = 0.001; 𝐼² = 0%), and increasing infection rate, including ventriculitis and meningitis (OR = 2.54; 95% CI [1.05, 6.19]; p = 0.040; 𝐼² = 51%). The results of this present study indicate that intrathecal nicardipine may be an effective therapeutic option for reducing the severity of vasospasm and improving mortality rates in patients with non-traumatic SAH. However, it may increase the risk of infections. Further research with randomized controlled trials is needed to confirm these findings and evaluate this treatment's long-term benefits and risks.
Indexed as
Identifiers
40295406What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.